Alliance addresses buy-side regulatory pressure

Microgen has teamed up with NumeriX and Independent Risk Monitoring to launch a Microgen Aptitude-based service to address the regulations arising from UCITS III, Mifid, and the increasing use of OTC derivatives in portfolios managed by buy-side firms. The solution - Microgen Independent Valuation and Risk (IVR) - is aimed at meeting the challenges facing asset managers and their service providers in relation to the increasing use of OTC derivative-based products. Microgen IVR provides an

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact [email protected] to find out more.

To continue reading...

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: